Biomarin Pharmaceutical Inc at SVB Leerink Global Healthcare Conference (Virtual) Transcript
Hello. Welcome to this fireside chat with BioMarin Pharmaceutical. I'm Joe Schwartz from the SVB Leerink Equity Research team. It's my pleasure to host management. Today, we're very pleased to have J.J. Bienaime, Chairman and CEO; Hank Fuchs, CMO; Brian Mueller, CFO. Welcome, gentlemen. Thanks for joining us.
Maybe we can start, J.J., by just having you give us a quick update on all of your activities and the news flow that investors should be on the lookout for this year.
So as you know, we reported our Q4 yesterday, and I would say that the essential nature of our medicine resulted in strong growth despite, as you know, the global pandemic and the delay in ROCTAVIAN approval. As you're excluding Kuvan, BioMarin revenues grew 13% in 2020 and generated $85 million of positive operating cash flow. The '20 -- we gave guidance for '21. Our revenues are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
